Patients who received placebo in SELECT were randomly assigned ( 1:1 ) to receive 150 mg or 300 mg subcutaneous daclizumab HYP every 4 weeks for 52 weeks ( treatment initiation group ) ; those who had received daclizumab HYP were randomly assigned ( 1:1 ) to continue their present dose with ( washout and re-initiation group ) or without ( continuous treatment group ) a washout period of 20 weeks .